 Alan Palestine
Concepts (683)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uveitis | 70 | 2024 | 127 | 7.720 |
Why?
| | Panuveitis | 4 | 2023 | 7 | 3.220 |
Why?
| | Fluocinolone Acetonide | 4 | 2024 | 19 | 2.490 |
Why?
| | Uveitis, Intermediate | 4 | 2023 | 8 | 2.370 |
Why?
| | Visual Acuity | 30 | 2024 | 320 | 2.340 |
Why?
| | Cataract | 6 | 2023 | 194 | 2.270 |
Why?
| | Glucocorticoids | 9 | 2024 | 575 | 1.970 |
Why?
| | Fluorescein Angiography | 18 | 2025 | 141 | 1.940 |
Why?
| | Eye Infections, Bacterial | 5 | 2020 | 26 | 1.850 |
Why?
| | Endophthalmitis | 6 | 2020 | 28 | 1.790 |
Why?
| | Retinopathy of Prematurity | 8 | 2020 | 138 | 1.790 |
Why?
| | Macular Edema | 5 | 2023 | 41 | 1.740 |
Why?
| | Scleritis | 3 | 2022 | 19 | 1.660 |
Why?
| | Vitrectomy | 8 | 2020 | 62 | 1.590 |
Why?
| | Corneal Ulcer | 2 | 2022 | 15 | 1.580 |
Why?
| | Tomography, Optical Coherence | 8 | 2025 | 182 | 1.560 |
Why?
| | Macular Degeneration | 9 | 2023 | 157 | 1.490 |
Why?
| | Geographic Atrophy | 8 | 2025 | 69 | 1.340 |
Why?
| | Cytomegalovirus Retinitis | 6 | 2024 | 18 | 1.290 |
Why?
| | Arthritis, Juvenile | 2 | 2022 | 54 | 1.280 |
Why?
| | Vitreous Body | 15 | 2022 | 102 | 1.280 |
Why?
| | Ocular Hypertension | 4 | 2022 | 64 | 1.110 |
Why?
| | Cyclosporins | 31 | 1991 | 59 | 1.020 |
Why?
| | Postoperative Complications | 7 | 2021 | 2479 | 1.010 |
Why?
| | Corneal Transplantation | 5 | 2025 | 13 | 0.990 |
Why?
| | Glaucoma | 3 | 2023 | 216 | 0.950 |
Why?
| | Cataract Extraction | 4 | 2023 | 96 | 0.940 |
Why?
| | Intraocular Pressure | 10 | 2024 | 296 | 0.940 |
Why?
| | Drug Costs | 2 | 2016 | 103 | 0.920 |
Why?
| | Retinal Vessels | 6 | 2021 | 63 | 0.890 |
Why?
| | Uveitis, Posterior | 5 | 2019 | 12 | 0.840 |
Why?
| | Inflammation | 10 | 2023 | 2664 | 0.830 |
Why?
| | Anterior Chamber | 5 | 2021 | 20 | 0.830 |
Why?
| | Humans | 177 | 2025 | 128524 | 0.830 |
Why?
| | Diabetic Retinopathy | 2 | 2022 | 171 | 0.820 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2020 | 573 | 0.820 |
Why?
| | Antirheumatic Agents | 2 | 2022 | 282 | 0.820 |
Why?
| | Retinal Detachment | 3 | 2020 | 56 | 0.820 |
Why?
| | Keratoconjunctivitis Sicca | 1 | 2022 | 4 | 0.810 |
Why?
| | Eye Diseases | 10 | 2020 | 78 | 0.810 |
Why?
| | Retinitis | 15 | 1993 | 19 | 0.790 |
Why?
| | Behcet Syndrome | 7 | 2021 | 18 | 0.780 |
Why?
| | Methotrexate | 3 | 2022 | 249 | 0.780 |
Why?
| | Health Care Costs | 2 | 2016 | 395 | 0.780 |
Why?
| | Retrospective Studies | 34 | 2024 | 14460 | 0.770 |
Why?
| | Wet Macular Degeneration | 5 | 2025 | 46 | 0.760 |
Why?
| | Retinal Drusen | 4 | 2024 | 31 | 0.750 |
Why?
| | Drug Implants | 6 | 2024 | 82 | 0.750 |
Why?
| | Retinal Diseases | 6 | 2020 | 86 | 0.750 |
Why?
| | Acquired Immunodeficiency Syndrome | 22 | 1996 | 222 | 0.740 |
Why?
| | Retinal Vasculitis | 1 | 2021 | 10 | 0.730 |
Why?
| | Azathioprine | 2 | 2022 | 49 | 0.730 |
Why?
| | Eye Banks | 1 | 2020 | 6 | 0.710 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2020 | 43 | 0.670 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 76 | 0.640 |
Why?
| | Registries | 7 | 2025 | 1878 | 0.640 |
Why?
| | Homosexuality, Male | 1 | 2020 | 176 | 0.640 |
Why?
| | Practice Patterns, Physicians' | 3 | 2016 | 1266 | 0.600 |
Why?
| | Cytomegalovirus | 3 | 2022 | 153 | 0.580 |
Why?
| | Surveys and Questionnaires | 8 | 2022 | 5346 | 0.570 |
Why?
| | International Classification of Diseases | 1 | 2018 | 124 | 0.570 |
Why?
| | Conjunctivitis | 3 | 2024 | 29 | 0.570 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2019 | 214 | 0.560 |
Why?
| | Fetal Membranes, Premature Rupture | 1 | 2017 | 35 | 0.550 |
Why?
| | Adrenal Cortex Hormones | 4 | 2023 | 518 | 0.550 |
Why?
| | Labor, Induced | 1 | 2017 | 30 | 0.550 |
Why?
| | Sarcoidosis | 9 | 2023 | 154 | 0.550 |
Why?
| | Labor, Obstetric | 1 | 2017 | 57 | 0.540 |
Why?
| | Rheumatologists | 1 | 2016 | 16 | 0.530 |
Why?
| | Ophthalmologists | 1 | 2016 | 11 | 0.530 |
Why?
| | Female | 106 | 2025 | 68127 | 0.530 |
Why?
| | Follow-Up Studies | 16 | 2025 | 4898 | 0.530 |
Why?
| | Adult | 75 | 2024 | 35315 | 0.520 |
Why?
| | Male | 90 | 2025 | 62883 | 0.520 |
Why?
| | Aged | 45 | 2025 | 21971 | 0.520 |
Why?
| | Polychondritis, Relapsing | 1 | 2015 | 2 | 0.510 |
Why?
| | Ear Auricle | 1 | 2015 | 11 | 0.510 |
Why?
| | Autoimmune Diseases | 20 | 2009 | 423 | 0.500 |
Why?
| | Middle Aged | 59 | 2025 | 30893 | 0.500 |
Why?
| | Insurance, Health | 2 | 2016 | 271 | 0.500 |
Why?
| | Vision Disorders | 2 | 2016 | 135 | 0.500 |
Why?
| | Neonatal Screening | 4 | 2018 | 163 | 0.480 |
Why?
| | Needles | 1 | 2015 | 57 | 0.480 |
Why?
| | Biopsy, Needle | 1 | 2015 | 189 | 0.470 |
Why?
| | Surgical Wound Infection | 1 | 2018 | 281 | 0.470 |
Why?
| | DNA, Viral | 1 | 2016 | 348 | 0.460 |
Why?
| | Diabetes Mellitus | 2 | 2022 | 1001 | 0.450 |
Why?
| | Multimodal Imaging | 2 | 2025 | 105 | 0.440 |
Why?
| | Choroid | 12 | 2024 | 61 | 0.430 |
Why?
| | Complement Activation | 3 | 2022 | 364 | 0.430 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 1108 | 0.430 |
Why?
| | Premature Birth | 1 | 2017 | 311 | 0.430 |
Why?
| | Databases, Factual | 1 | 2018 | 1268 | 0.410 |
Why?
| | Aged, 80 and over | 16 | 2025 | 7040 | 0.410 |
Why?
| | Cytomegalovirus Infections | 12 | 1999 | 187 | 0.410 |
Why?
| | Ophthalmology | 3 | 2022 | 81 | 0.410 |
Why?
| | Immunosuppressive Agents | 5 | 2022 | 686 | 0.410 |
Why?
| | Vaccination | 1 | 2021 | 1336 | 0.400 |
Why?
| | Bacteria | 2 | 2018 | 811 | 0.400 |
Why?
| | Gestational Age | 8 | 2020 | 862 | 0.400 |
Why?
| | Colorado | 11 | 2025 | 4392 | 0.400 |
Why?
| | Melanoma | 1 | 2019 | 749 | 0.400 |
Why?
| | Antiviral Agents | 11 | 2022 | 704 | 0.390 |
Why?
| | Steroids | 2 | 2023 | 148 | 0.390 |
Why?
| | Skin Neoplasms | 2 | 2019 | 832 | 0.380 |
Why?
| | Placenta | 1 | 2018 | 714 | 0.380 |
Why?
| | Antineoplastic Agents | 3 | 2020 | 2058 | 0.380 |
Why?
| | Anti-Bacterial Agents | 3 | 2024 | 1667 | 0.380 |
Why?
| | Intravitreal Injections | 2 | 2024 | 54 | 0.380 |
Why?
| | AIDS-Related Opportunistic Infections | 3 | 2022 | 121 | 0.370 |
Why?
| | Graft Rejection | 4 | 2025 | 557 | 0.360 |
Why?
| | Electronic Health Records | 1 | 2018 | 967 | 0.360 |
Why?
| | Fundus Oculi | 9 | 2025 | 61 | 0.360 |
Why?
| | Macula Lutea | 3 | 2020 | 18 | 0.350 |
Why?
| | Ciliary Body | 9 | 2018 | 33 | 0.350 |
Why?
| | Biomarkers | 9 | 2025 | 3881 | 0.350 |
Why?
| | Trabeculectomy | 2 | 2022 | 71 | 0.340 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1490 | 0.340 |
Why?
| | Complement Factor B | 2 | 2022 | 105 | 0.340 |
Why?
| | Organ Transplantation | 2 | 2024 | 219 | 0.330 |
Why?
| | Ganciclovir | 9 | 2022 | 51 | 0.320 |
Why?
| | Glaucoma, Open-Angle | 2 | 2022 | 101 | 0.310 |
Why?
| | Aqueous Humor | 4 | 2022 | 33 | 0.310 |
Why?
| | United States | 11 | 2023 | 13876 | 0.310 |
Why?
| | Antigens | 14 | 1990 | 352 | 0.300 |
Why?
| | Complement System Proteins | 3 | 2022 | 306 | 0.300 |
Why?
| | Adolescent | 29 | 2024 | 20213 | 0.290 |
Why?
| | Conjunctival Diseases | 3 | 2017 | 17 | 0.290 |
Why?
| | Incidence | 7 | 2024 | 2619 | 0.290 |
Why?
| | Eye Proteins | 7 | 1990 | 87 | 0.290 |
Why?
| | Cyclosporine | 2 | 2022 | 168 | 0.290 |
Why?
| | Retina | 18 | 1993 | 280 | 0.280 |
Why?
| | Birth Weight | 4 | 2020 | 498 | 0.270 |
Why?
| | Uveitis, Anterior | 4 | 2018 | 13 | 0.270 |
Why?
| | Corneal Diseases | 5 | 2017 | 34 | 0.270 |
Why?
| | Child | 22 | 2024 | 20721 | 0.260 |
Why?
| | Risk Factors | 11 | 2024 | 9727 | 0.250 |
Why?
| | Cross-Sectional Studies | 6 | 2024 | 5040 | 0.250 |
Why?
| | Opportunistic Infections | 4 | 1991 | 47 | 0.250 |
Why?
| | Pemphigoid, Benign Mucous Membrane | 2 | 2024 | 6 | 0.250 |
Why?
| | Adalimumab | 2 | 2022 | 44 | 0.250 |
Why?
| | Biological Factors | 2 | 2022 | 37 | 0.250 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 42 | 0.240 |
Why?
| | Bromocriptine | 4 | 1990 | 28 | 0.240 |
Why?
| | Time Factors | 12 | 2021 | 6503 | 0.230 |
Why?
| | Child, Preschool | 10 | 2024 | 10373 | 0.230 |
Why?
| | Young Adult | 8 | 2024 | 12320 | 0.230 |
Why?
| | Papilledema | 2 | 2024 | 39 | 0.230 |
Why?
| | Retinal Pigment Epithelium | 2 | 2024 | 69 | 0.230 |
Why?
| | Tuberculosis, Ocular | 1 | 2024 | 7 | 0.230 |
Why?
| | Specialization | 2 | 2016 | 144 | 0.230 |
Why?
| | Retinal Vein Occlusion | 1 | 2004 | 13 | 0.220 |
Why?
| | Infant | 9 | 2022 | 8913 | 0.220 |
Why?
| | Laser Therapy | 5 | 2021 | 130 | 0.220 |
Why?
| | Infant, Premature | 2 | 2019 | 536 | 0.220 |
Why?
| | Interferon-gamma Release Tests | 1 | 2024 | 32 | 0.220 |
Why?
| | Fluoresceins | 5 | 1989 | 47 | 0.220 |
Why?
| | Cohort Studies | 7 | 2020 | 5369 | 0.220 |
Why?
| | Mycophenolic Acid | 2 | 2022 | 92 | 0.220 |
Why?
| | Optic Disk | 1 | 2024 | 40 | 0.210 |
Why?
| | Phacoemulsification | 3 | 2019 | 115 | 0.210 |
Why?
| | Infant, Very Low Birth Weight | 3 | 2018 | 67 | 0.210 |
Why?
| | Anti-Inflammatory Agents | 3 | 2022 | 469 | 0.210 |
Why?
| | Algorithms | 4 | 2018 | 1616 | 0.200 |
Why?
| | Quality of Life | 3 | 2023 | 2680 | 0.200 |
Why?
| | Etanercept | 1 | 2022 | 58 | 0.200 |
Why?
| | Histocompatibility Antigens Class II | 9 | 1994 | 359 | 0.200 |
Why?
| | Foscarnet | 4 | 1996 | 19 | 0.200 |
Why?
| | Eye Neoplasms | 3 | 2017 | 16 | 0.200 |
Why?
| | Reference Standards | 2 | 2022 | 170 | 0.190 |
Why?
| | Tacrolimus | 1 | 2022 | 138 | 0.190 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 7 | 0.190 |
Why?
| | Albumins | 1 | 2022 | 101 | 0.190 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.190 |
Why?
| | Treatment Outcome | 10 | 2024 | 10163 | 0.190 |
Why?
| | Eye Infections, Viral | 2 | 1991 | 6 | 0.190 |
Why?
| | Antibodies, Monoclonal | 12 | 2020 | 1355 | 0.180 |
Why?
| | Capsule Opacification | 1 | 2021 | 21 | 0.180 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 22 | 0.180 |
Why?
| | Rats, Inbred Lew | 18 | 1994 | 92 | 0.180 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.180 |
Why?
| | Sensitivity and Specificity | 4 | 2018 | 1820 | 0.180 |
Why?
| | T-Lymphocytes, Helper-Inducer | 8 | 1994 | 136 | 0.180 |
Why?
| | Laser Coagulation | 2 | 2018 | 57 | 0.180 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2020 | 16 | 0.170 |
Why?
| | Anemia, Sickle Cell | 1 | 2004 | 252 | 0.170 |
Why?
| | Administration, Topical | 4 | 2016 | 144 | 0.170 |
Why?
| | Scleral Buckling | 1 | 2019 | 18 | 0.170 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 22 | 0.170 |
Why?
| | Endotoxins | 3 | 1991 | 216 | 0.170 |
Why?
| | Diagnostic Techniques, Ophthalmological | 2 | 2018 | 38 | 0.170 |
Why?
| | Multiple Sclerosis | 3 | 2023 | 434 | 0.160 |
Why?
| | Canada | 1 | 2020 | 345 | 0.160 |
Why?
| | Infant, Newborn | 7 | 2020 | 5687 | 0.160 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 34 | 0.160 |
Why?
| | Transplantation, Autologous | 1 | 2020 | 215 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2022 | 1190 | 0.160 |
Why?
| | Complement C3a | 1 | 2019 | 40 | 0.160 |
Why?
| | Prospective Studies | 8 | 2025 | 7043 | 0.160 |
Why?
| | Acyclovir | 5 | 2001 | 93 | 0.160 |
Why?
| | Pyrimidinones | 1 | 2019 | 102 | 0.150 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 51 | 0.150 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 142 | 0.150 |
Why?
| | Computer Systems | 1 | 2018 | 44 | 0.150 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 18 | 0.150 |
Why?
| | Decision Making | 2 | 2016 | 850 | 0.150 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 223 | 0.150 |
Why?
| | Viral Load | 2 | 2016 | 450 | 0.150 |
Why?
| | Rats | 25 | 2025 | 5168 | 0.150 |
Why?
| | Organophosphonates | 1 | 1998 | 91 | 0.150 |
Why?
| | Disease-Free Survival | 1 | 2019 | 656 | 0.140 |
Why?
| | Risk | 4 | 2018 | 852 | 0.140 |
Why?
| | Biological Products | 1 | 2021 | 200 | 0.140 |
Why?
| | Metformin | 1 | 2021 | 311 | 0.140 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 178 | 0.140 |
Why?
| | Farber Lipogranulomatosis | 1 | 2017 | 4 | 0.140 |
Why?
| | Reoperation | 1 | 2020 | 550 | 0.140 |
Why?
| | Amnion | 1 | 2017 | 25 | 0.140 |
Why?
| | Synovitis | 1 | 2017 | 25 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 1358 | 0.140 |
Why?
| | Arrestin | 13 | 1990 | 13 | 0.140 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2017 | 38 | 0.140 |
Why?
| | Ophthalmoscopy | 1 | 2016 | 34 | 0.130 |
Why?
| | Parity | 1 | 2017 | 120 | 0.130 |
Why?
| | Cicatrix | 1 | 2017 | 58 | 0.130 |
Why?
| | Medical Informatics | 1 | 2017 | 99 | 0.130 |
Why?
| | Herpes Zoster | 2 | 2009 | 317 | 0.130 |
Why?
| | Infant, Low Birth Weight | 1 | 2017 | 132 | 0.130 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 1019 | 0.130 |
Why?
| | Terminology as Topic | 1 | 2017 | 199 | 0.130 |
Why?
| | Arthritis | 1 | 2017 | 114 | 0.130 |
Why?
| | Transplantation, Homologous | 2 | 2016 | 396 | 0.130 |
Why?
| | Burnout, Professional | 1 | 2022 | 408 | 0.130 |
Why?
| | Lymphocytes | 9 | 1991 | 366 | 0.130 |
Why?
| | T-Lymphocytes | 12 | 2022 | 1922 | 0.120 |
Why?
| | Disease Management | 1 | 2019 | 588 | 0.120 |
Why?
| | Recovery of Function | 1 | 2019 | 643 | 0.120 |
Why?
| | Endoscopy | 1 | 2018 | 267 | 0.120 |
Why?
| | Microbiological Techniques | 1 | 2015 | 30 | 0.120 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 173 | 0.120 |
Why?
| | Colony Count, Microbial | 1 | 2015 | 116 | 0.120 |
Why?
| | Weight Gain | 2 | 2016 | 505 | 0.120 |
Why?
| | Pregnancy | 2 | 2018 | 6297 | 0.120 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 307 | 0.120 |
Why?
| | Rheumatology | 1 | 2016 | 111 | 0.120 |
Why?
| | Hematologic Neoplasms | 1 | 2016 | 139 | 0.120 |
Why?
| | Phosphonoacetic Acid | 2 | 1991 | 10 | 0.120 |
Why?
| | Lymphocyte Activation | 8 | 1990 | 1098 | 0.110 |
Why?
| | Health Care Surveys | 1 | 2016 | 557 | 0.110 |
Why?
| | Chorioretinitis | 2 | 1992 | 3 | 0.110 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2019 | 375 | 0.110 |
Why?
| | Toxoplasmosis, Ocular | 2 | 1994 | 2 | 0.110 |
Why?
| | Reproducibility of Results | 2 | 2018 | 3023 | 0.110 |
Why?
| | Fetus | 1 | 2018 | 758 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 302 | 0.110 |
Why?
| | Physicians | 1 | 2022 | 860 | 0.110 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 872 | 0.110 |
Why?
| | Lymphoma, B-Cell | 2 | 1993 | 104 | 0.110 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 1998 | 1046 | 0.100 |
Why?
| | Kidney Diseases | 6 | 1989 | 368 | 0.100 |
Why?
| | Research Design | 1 | 2019 | 1038 | 0.100 |
Why?
| | Patient Selection | 1 | 2016 | 661 | 0.100 |
Why?
| | HIV-1 | 1 | 1998 | 840 | 0.100 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 1992 | 113 | 0.100 |
Why?
| | Iris | 3 | 1991 | 19 | 0.100 |
Why?
| | Creatinine | 7 | 1992 | 475 | 0.100 |
Why?
| | Health Surveys | 1 | 2014 | 492 | 0.100 |
Why?
| | HLA Antigens | 7 | 1991 | 235 | 0.100 |
Why?
| | Risk Assessment | 2 | 2019 | 3256 | 0.100 |
Why?
| | Pars Planitis | 1 | 1992 | 1 | 0.100 |
Why?
| | Mothers | 1 | 2018 | 728 | 0.100 |
Why?
| | Retinal Necrosis Syndrome, Acute | 1 | 1991 | 7 | 0.090 |
Why?
| | Injections, Intravenous | 7 | 1999 | 193 | 0.090 |
Why?
| | Immunologic Factors | 2 | 2024 | 229 | 0.090 |
Why?
| | Capillary Permeability | 2 | 1991 | 131 | 0.090 |
Why?
| | Animals | 35 | 2025 | 34501 | 0.090 |
Why?
| | Patient Care Team | 1 | 2016 | 600 | 0.090 |
Why?
| | HIV | 4 | 2020 | 226 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1565 | 0.090 |
Why?
| | Clinical Competence | 1 | 2018 | 1014 | 0.090 |
Why?
| | Bacterial Infections | 3 | 1989 | 227 | 0.090 |
Why?
| | Antigens, Surface | 3 | 1989 | 150 | 0.090 |
Why?
| | Toxoplasma | 2 | 1994 | 39 | 0.090 |
Why?
| | Cytophagaceae | 1 | 1990 | 1 | 0.090 |
Why?
| | Capnocytophaga | 1 | 1990 | 2 | 0.090 |
Why?
| | Granuloma | 4 | 2023 | 85 | 0.080 |
Why?
| | Urine | 1 | 1989 | 54 | 0.080 |
Why?
| | Antigens, Protozoan | 1 | 1989 | 22 | 0.080 |
Why?
| | Sebaceous Gland Neoplasms | 1 | 1989 | 2 | 0.080 |
Why?
| | Eyelid Neoplasms | 1 | 1989 | 8 | 0.080 |
Why?
| | Blood Chemical Analysis | 1 | 1989 | 96 | 0.080 |
Why?
| | Odds Ratio | 4 | 2019 | 1022 | 0.080 |
Why?
| | Drug Therapy, Combination | 5 | 1998 | 1009 | 0.080 |
Why?
| | Tonometry, Ocular | 2 | 2019 | 88 | 0.080 |
Why?
| | Eye | 7 | 1988 | 103 | 0.070 |
Why?
| | Disease Progression | 3 | 2025 | 2603 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2024 | 1943 | 0.070 |
Why?
| | Postoperative Period | 2 | 2019 | 322 | 0.070 |
Why?
| | Disease Models, Animal | 4 | 2025 | 3943 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 8 | 2019 | 814 | 0.070 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 1987 | 17 | 0.070 |
Why?
| | Antibody Formation | 3 | 1985 | 287 | 0.070 |
Why?
| | Dextrans | 1 | 1987 | 82 | 0.070 |
Why?
| | Fanconi Syndrome | 1 | 1986 | 2 | 0.070 |
Why?
| | Escherichia coli | 1 | 1991 | 770 | 0.070 |
Why?
| | Autoantibodies | 6 | 1992 | 1463 | 0.070 |
Why?
| | Prednisolone | 2 | 2020 | 82 | 0.070 |
Why?
| | Cell Movement | 2 | 1988 | 937 | 0.060 |
Why?
| | Lymphocyte Transfusion | 1 | 1986 | 20 | 0.060 |
Why?
| | Immunoenzyme Techniques | 8 | 1991 | 206 | 0.060 |
Why?
| | Infliximab | 2 | 2021 | 100 | 0.060 |
Why?
| | Interferometry | 1 | 1985 | 4 | 0.060 |
Why?
| | Lasers | 2 | 1985 | 132 | 0.060 |
Why?
| | Phenotype | 4 | 2022 | 3050 | 0.060 |
Why?
| | Lenses, Intraocular | 2 | 2021 | 43 | 0.060 |
Why?
| | Panophthalmitis | 1 | 1985 | 2 | 0.060 |
Why?
| | Lubricant Eye Drops | 1 | 2024 | 9 | 0.060 |
Why?
| | Uveomeningoencephalitic Syndrome | 3 | 1990 | 7 | 0.060 |
Why?
| | Protein S Deficiency | 1 | 2004 | 5 | 0.060 |
Why?
| | Ophthalmic Solutions | 1 | 2024 | 73 | 0.060 |
Why?
| | Choroiditis | 4 | 1991 | 6 | 0.060 |
Why?
| | Biopsy | 5 | 1993 | 1085 | 0.060 |
Why?
| | Endemic Diseases | 1 | 2024 | 30 | 0.060 |
Why?
| | Myopia | 1 | 1984 | 47 | 0.060 |
Why?
| | Microscopy, Electron | 8 | 1988 | 417 | 0.050 |
Why?
| | Viremia | 1 | 2024 | 130 | 0.050 |
Why?
| | Tretinoin | 1 | 1984 | 124 | 0.050 |
Why?
| | Phagocyte Bactericidal Dysfunction | 1 | 1983 | 12 | 0.050 |
Why?
| | Tears | 4 | 1987 | 28 | 0.050 |
Why?
| | Retinal Artery | 2 | 1987 | 16 | 0.050 |
Why?
| | Ophthalmia, Sympathetic | 3 | 1990 | 3 | 0.050 |
Why?
| | Keratoplasty, Penetrating | 2 | 1994 | 4 | 0.050 |
Why?
| | Transplant Recipients | 1 | 2024 | 151 | 0.050 |
Why?
| | Immunologic Memory | 1 | 1985 | 339 | 0.050 |
Why?
| | Immunocompromised Host | 1 | 2024 | 195 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 213 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2025 | 2697 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2020 | 3326 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Immunohistochemistry | 6 | 1993 | 1669 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 1989 | 888 | 0.050 |
Why?
| | Deltaretrovirus | 3 | 1986 | 12 | 0.050 |
Why?
| | Aneurysm | 1 | 1982 | 30 | 0.050 |
Why?
| | Cavernous Sinus | 1 | 1981 | 15 | 0.050 |
Why?
| | 2-Aminopurine | 1 | 2001 | 8 | 0.050 |
Why?
| | Herpes Zoster Ophthalmicus | 1 | 2001 | 5 | 0.050 |
Why?
| | Infusions, Intravenous | 2 | 2020 | 384 | 0.050 |
Why?
| | Fibrinogen | 1 | 2022 | 158 | 0.050 |
Why?
| | Arteriovenous Fistula | 1 | 1981 | 36 | 0.050 |
Why?
| | Transplantation Tolerance | 1 | 2021 | 34 | 0.050 |
Why?
| | Pigment Epithelium of Eye | 4 | 1990 | 34 | 0.050 |
Why?
| | Abatacept | 1 | 2021 | 47 | 0.050 |
Why?
| | Tertiary Healthcare | 1 | 2020 | 29 | 0.040 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 55 | 0.040 |
Why?
| | Cyclopentolate | 1 | 2020 | 3 | 0.040 |
Why?
| | Microscopy, Acoustic | 1 | 2020 | 8 | 0.040 |
Why?
| | Gonioscopy | 1 | 2020 | 6 | 0.040 |
Why?
| | Administration, Ophthalmic | 1 | 2020 | 14 | 0.040 |
Why?
| | Mycobacterium tuberculosis | 1 | 2024 | 314 | 0.040 |
Why?
| | Muscarinic Antagonists | 1 | 2020 | 26 | 0.040 |
Why?
| | Kidney | 3 | 1989 | 1305 | 0.040 |
Why?
| | Amyloidosis | 1 | 2020 | 39 | 0.040 |
Why?
| | Epithelium | 6 | 1991 | 306 | 0.040 |
Why?
| | Carotid Arteries | 1 | 1981 | 206 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 91 | 0.040 |
Why?
| | Immunization, Passive | 3 | 1988 | 85 | 0.040 |
Why?
| | Cornea | 4 | 1989 | 114 | 0.040 |
Why?
| | Anticoagulants | 1 | 2004 | 613 | 0.040 |
Why?
| | Drug Combinations | 1 | 2020 | 323 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2021 | 396 | 0.040 |
Why?
| | Sarcoma, Kaposi | 4 | 1999 | 76 | 0.040 |
Why?
| | Cytosine | 1 | 1998 | 45 | 0.040 |
Why?
| | Hypertension | 5 | 1991 | 1238 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2024 | 1936 | 0.040 |
Why?
| | Trabecular Meshwork | 1 | 2019 | 79 | 0.040 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 265 | 0.040 |
Why?
| | Prolactin | 2 | 1988 | 97 | 0.040 |
Why?
| | Conjunctiva | 3 | 1989 | 51 | 0.040 |
Why?
| | Logistic Models | 2 | 2019 | 1975 | 0.040 |
Why?
| | Organophosphorus Compounds | 1 | 1998 | 77 | 0.040 |
Why?
| | Retinol-Binding Proteins | 2 | 1988 | 14 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2020 | 473 | 0.040 |
Why?
| | Fluorometholone | 1 | 2017 | 4 | 0.040 |
Why?
| | Group Processes | 1 | 2017 | 56 | 0.030 |
Why?
| | Drug Evaluation | 2 | 1988 | 80 | 0.030 |
Why?
| | Administration, Oral | 3 | 1999 | 757 | 0.030 |
Why?
| | North America | 1 | 2018 | 289 | 0.030 |
Why?
| | Nod2 Signaling Adaptor Protein | 1 | 2017 | 33 | 0.030 |
Why?
| | Chemotaxis, Leukocyte | 2 | 1987 | 136 | 0.030 |
Why?
| | Interferon-gamma | 2 | 1991 | 761 | 0.030 |
Why?
| | HLA-DR Antigens | 5 | 1991 | 225 | 0.030 |
Why?
| | Cytokines | 1 | 2025 | 1985 | 0.030 |
Why?
| | Observer Variation | 1 | 2017 | 315 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 727 | 0.030 |
Why?
| | Properdin | 1 | 1976 | 8 | 0.030 |
Why?
| | Cattle | 5 | 1991 | 962 | 0.030 |
Why?
| | Rats, Inbred Strains | 5 | 1987 | 356 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 501 | 0.030 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2016 | 20 | 0.030 |
Why?
| | Plasma Cells | 2 | 1987 | 65 | 0.030 |
Why?
| | Drug Resistance, Microbial | 1 | 1996 | 63 | 0.030 |
Why?
| | Proteins | 2 | 2020 | 936 | 0.030 |
Why?
| | Chronic Disease | 4 | 1990 | 1701 | 0.030 |
Why?
| | Magnesium | 2 | 1986 | 151 | 0.030 |
Why?
| | Syndrome | 2 | 1987 | 335 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1494 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 608 | 0.030 |
Why?
| | HIV Infections | 1 | 2009 | 2703 | 0.030 |
Why?
| | Blood Proteins | 2 | 1989 | 236 | 0.030 |
Why?
| | Glycoproteins | 1 | 1976 | 337 | 0.030 |
Why?
| | Conjunctival Neoplasms | 2 | 1984 | 6 | 0.030 |
Why?
| | Retinal Hemorrhage | 2 | 1986 | 18 | 0.030 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2017 | 224 | 0.030 |
Why?
| | Diagnosis, Differential | 2 | 1988 | 1416 | 0.030 |
Why?
| | Recurrence | 2 | 1988 | 1001 | 0.030 |
Why?
| | Proteomics | 1 | 2020 | 1004 | 0.030 |
Why?
| | Granulomatous Disease, Chronic | 2 | 1983 | 53 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 4 | 1989 | 374 | 0.030 |
Why?
| | Models, Biological | 2 | 2016 | 1693 | 0.030 |
Why?
| | Antibodies, Antinuclear | 2 | 1992 | 65 | 0.030 |
Why?
| | Immunity, Cellular | 2 | 1985 | 267 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 7 | 1994 | 374 | 0.030 |
Why?
| | Immunization | 2 | 1985 | 411 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1214 | 0.030 |
Why?
| | Dinoprostone | 2 | 1990 | 187 | 0.020 |
Why?
| | Cells, Cultured | 5 | 1991 | 4008 | 0.020 |
Why?
| | Eye Infections | 1 | 1992 | 2 | 0.020 |
Why?
| | Models, Statistical | 1 | 2016 | 625 | 0.020 |
Why?
| | Cell Line | 5 | 1991 | 2731 | 0.020 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 2 | 1989 | 87 | 0.020 |
Why?
| | Sepsis | 2 | 1984 | 556 | 0.020 |
Why?
| | Epitopes | 3 | 1990 | 466 | 0.020 |
Why?
| | Kinetics | 2 | 1988 | 1616 | 0.020 |
Why?
| | Propionibacterium acnes | 1 | 1991 | 9 | 0.020 |
Why?
| | Indomethacin | 2 | 1990 | 77 | 0.020 |
Why?
| | Transforming Growth Factor beta | 2 | 1991 | 448 | 0.020 |
Why?
| | Biological Transport, Active | 1 | 1991 | 72 | 0.020 |
Why?
| | Dogs | 2 | 1990 | 366 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2736 | 0.020 |
Why?
| | Microcirculation | 1 | 1991 | 137 | 0.020 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 1990 | 6 | 0.020 |
Why?
| | B-Lymphocytes | 2 | 1987 | 820 | 0.020 |
Why?
| | Random Allocation | 2 | 1988 | 346 | 0.020 |
Why?
| | Coronary Circulation | 1 | 1991 | 136 | 0.020 |
Why?
| | Cefazolin | 1 | 1990 | 16 | 0.020 |
Why?
| | Endothelium, Corneal | 1 | 1990 | 16 | 0.020 |
Why?
| | Recombinant Proteins | 2 | 1991 | 1284 | 0.020 |
Why?
| | Fluorescein | 1 | 1989 | 25 | 0.020 |
Why?
| | Protein Binding | 2 | 1989 | 2097 | 0.020 |
Why?
| | Keratitis | 2 | 1994 | 11 | 0.020 |
Why?
| | Flow Cytometry | 2 | 1992 | 1141 | 0.020 |
Why?
| | Kidney Function Tests | 2 | 1989 | 145 | 0.020 |
Why?
| | Osmolar Concentration | 1 | 1989 | 162 | 0.020 |
Why?
| | Diagnostic Errors | 1 | 1990 | 160 | 0.020 |
Why?
| | Retroviridae Proteins | 1 | 1989 | 11 | 0.020 |
Why?
| | Hemocyanins | 2 | 1988 | 61 | 0.020 |
Why?
| | Antimetabolites | 1 | 1989 | 22 | 0.020 |
Why?
| | Alkylating Agents | 1 | 1989 | 24 | 0.020 |
Why?
| | Drug Eruptions | 1 | 1989 | 26 | 0.020 |
Why?
| | Heptanoates | 1 | 1988 | 2 | 0.020 |
Why?
| | Interferon Type I | 1 | 1990 | 140 | 0.020 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1989 | 33 | 0.020 |
Why?
| | Suramin | 1 | 1988 | 6 | 0.020 |
Why?
| | Candidiasis | 1 | 1989 | 53 | 0.020 |
Why?
| | HIV Envelope Protein gp120 | 1 | 1989 | 57 | 0.020 |
Why?
| | Toxoplasmosis | 1 | 1989 | 37 | 0.020 |
Why?
| | Lung Diseases | 2 | 1986 | 722 | 0.020 |
Why?
| | Receptors, Virus | 1 | 1989 | 83 | 0.020 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 1989 | 81 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 1988 | 62 | 0.020 |
Why?
| | Lens, Crystalline | 1 | 1990 | 100 | 0.020 |
Why?
| | Mycobacterium Infections | 1 | 1989 | 62 | 0.020 |
Why?
| | Injections | 1 | 1989 | 170 | 0.020 |
Why?
| | Placebos | 1 | 1988 | 201 | 0.020 |
Why?
| | Dexamethasone | 2 | 1987 | 336 | 0.020 |
Why?
| | Antigen-Antibody Complex | 2 | 1985 | 84 | 0.020 |
Why?
| | Corneal Injuries | 1 | 1989 | 41 | 0.020 |
Why?
| | Central Nervous System Diseases | 1 | 1989 | 66 | 0.020 |
Why?
| | HIV Seropositivity | 1 | 1989 | 119 | 0.020 |
Why?
| | Sugar Alcohol Dehydrogenases | 1 | 1987 | 2 | 0.020 |
Why?
| | Imidazolidines | 1 | 1987 | 10 | 0.020 |
Why?
| | Elapid Venoms | 1 | 1987 | 17 | 0.020 |
Why?
| | Colchicine | 1 | 1987 | 25 | 0.020 |
Why?
| | Blood-Retinal Barrier | 1 | 1987 | 12 | 0.020 |
Why?
| | Aldehyde Reductase | 1 | 1987 | 27 | 0.020 |
Why?
| | Specific Gravity | 1 | 1987 | 10 | 0.020 |
Why?
| | Community Health Services | 1 | 2009 | 225 | 0.020 |
Why?
| | Receptors, Interleukin-2 | 1 | 1987 | 65 | 0.020 |
Why?
| | Pituitary-Adrenal System | 1 | 1989 | 143 | 0.020 |
Why?
| | Antigens, Differentiation | 1 | 1987 | 82 | 0.020 |
Why?
| | Herpesviridae Infections | 1 | 1989 | 134 | 0.020 |
Why?
| | Galactosemias | 1 | 1987 | 15 | 0.020 |
Why?
| | Prednisone | 2 | 1986 | 236 | 0.020 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 1987 | 6 | 0.020 |
Why?
| | Drug Interactions | 1 | 1989 | 360 | 0.020 |
Why?
| | Onchocerciasis | 1 | 1987 | 7 | 0.020 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 1989 | 176 | 0.020 |
Why?
| | Down-Regulation | 1 | 1990 | 629 | 0.020 |
Why?
| | Organ Specificity | 1 | 1987 | 291 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 1990 | 538 | 0.020 |
Why?
| | Sclera | 1 | 1987 | 36 | 0.020 |
Why?
| | Molecular Weight | 1 | 1987 | 331 | 0.020 |
Why?
| | Macaca mulatta | 1 | 1987 | 146 | 0.020 |
Why?
| | Heart Rate | 1 | 1991 | 804 | 0.020 |
Why?
| | Dihydroergotoxine | 1 | 1986 | 1 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 1990 | 856 | 0.020 |
Why?
| | Imidazoles | 1 | 1987 | 228 | 0.020 |
Why?
| | Indium | 1 | 1986 | 9 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 1987 | 209 | 0.020 |
Why?
| | Radioisotopes | 1 | 1986 | 31 | 0.020 |
Why?
| | Muramidase | 1 | 1986 | 75 | 0.020 |
Why?
| | Peritoneal Cavity | 1 | 1986 | 30 | 0.020 |
Why?
| | Wound Healing | 1 | 1989 | 310 | 0.020 |
Why?
| | Mutation | 1 | 2017 | 3692 | 0.020 |
Why?
| | Immune Tolerance | 1 | 1988 | 345 | 0.020 |
Why?
| | Serum Albumin | 1 | 1986 | 145 | 0.020 |
Why?
| | Reference Values | 4 | 1989 | 780 | 0.020 |
Why?
| | Osteoporosis | 1 | 1989 | 233 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1990 | 685 | 0.020 |
Why?
| | Prognosis | 2 | 1985 | 3780 | 0.020 |
Why?
| | Double-Blind Method | 3 | 2001 | 1860 | 0.020 |
Why?
| | Connective Tissue | 1 | 1985 | 38 | 0.020 |
Why?
| | Vascular Diseases | 1 | 1988 | 236 | 0.020 |
Why?
| | Acute Disease | 2 | 1987 | 968 | 0.020 |
Why?
| | Rabbits | 1 | 1986 | 761 | 0.020 |
Why?
| | Tetanus Toxoid | 1 | 1985 | 37 | 0.020 |
Why?
| | Pigmentation Disorders | 1 | 1985 | 9 | 0.020 |
Why?
| | Tissue Distribution | 1 | 1985 | 290 | 0.010 |
Why?
| | Salmonella typhimurium | 1 | 1986 | 176 | 0.010 |
Why?
| | Antibodies | 1 | 1987 | 391 | 0.010 |
Why?
| | Retinitis Pigmentosa | 1 | 1984 | 20 | 0.010 |
Why?
| | Potassium | 1 | 1985 | 138 | 0.010 |
Why?
| | Lymphadenitis | 1 | 1984 | 5 | 0.010 |
Why?
| | Kidney Glomerulus | 1 | 1985 | 106 | 0.010 |
Why?
| | Blood Sedimentation | 1 | 1984 | 34 | 0.010 |
Why?
| | Fibrosis | 1 | 1987 | 522 | 0.010 |
Why?
| | Kidney Tubules, Proximal | 1 | 1985 | 125 | 0.010 |
Why?
| | Chlorides | 1 | 1985 | 138 | 0.010 |
Why?
| | Oculomotor Muscles | 1 | 1984 | 38 | 0.010 |
Why?
| | Isotretinoin | 1 | 1984 | 23 | 0.010 |
Why?
| | Peptides | 1 | 1990 | 909 | 0.010 |
Why?
| | Acne Vulgaris | 1 | 1984 | 27 | 0.010 |
Why?
| | Complement C3 | 1 | 1985 | 198 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2009 | 727 | 0.010 |
Why?
| | Uveal Diseases | 1 | 1983 | 5 | 0.010 |
Why?
| | Optic Neuritis | 1 | 1984 | 38 | 0.010 |
Why?
| | Chediak-Higashi Syndrome | 1 | 1983 | 7 | 0.010 |
Why?
| | Uric Acid | 1 | 1984 | 161 | 0.010 |
Why?
| | Carbon Dioxide | 1 | 1985 | 261 | 0.010 |
Why?
| | Rats, Inbred BN | 2 | 1994 | 53 | 0.010 |
Why?
| | Anemia | 1 | 1984 | 156 | 0.010 |
Why?
| | Kidney Failure, Chronic | 1 | 1989 | 535 | 0.010 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 1984 | 134 | 0.010 |
Why?
| | Liver Diseases | 1 | 1986 | 285 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1986 | 1209 | 0.010 |
Why?
| | Fluorometry | 1 | 1981 | 17 | 0.010 |
Why?
| | Immunochemistry | 3 | 1986 | 13 | 0.010 |
Why?
| | Liver | 1 | 1990 | 1827 | 0.010 |
Why?
| | Melanosis | 1 | 1981 | 16 | 0.010 |
Why?
| | Computers | 1 | 1981 | 65 | 0.010 |
Why?
| | Histocytochemistry | 3 | 1986 | 81 | 0.010 |
Why?
| | Eyelid Diseases | 1 | 1981 | 18 | 0.010 |
Why?
| | Edema | 1 | 1982 | 125 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 1985 | 837 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2001 | 318 | 0.010 |
Why?
| | Calcium | 1 | 1986 | 1178 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 1994 | 168 | 0.010 |
Why?
| | HLA-DQ Antigens | 2 | 1991 | 179 | 0.010 |
Why?
| | Protease Inhibitors | 1 | 1999 | 103 | 0.010 |
Why?
| | Permeability | 2 | 1987 | 156 | 0.010 |
Why?
| | Arthus Reaction | 2 | 1987 | 8 | 0.010 |
Why?
| | Sucrose | 2 | 1987 | 95 | 0.010 |
Why?
| | Photoreceptor Cells | 2 | 1987 | 15 | 0.010 |
Why?
| | Survival Analysis | 1 | 1999 | 1265 | 0.010 |
Why?
| | Immunologic Techniques | 2 | 1986 | 38 | 0.010 |
Why?
| | Macrophages | 2 | 1994 | 1463 | 0.010 |
Why?
| | Transplantation, Isogeneic | 1 | 1994 | 17 | 0.010 |
Why?
| | Tissue Donors | 2 | 1989 | 386 | 0.010 |
Why?
| | Blotting, Southern | 1 | 1994 | 68 | 0.010 |
Why?
| | DNA, Protozoan | 1 | 1994 | 26 | 0.010 |
Why?
| | Shock, Septic | 1 | 1976 | 206 | 0.010 |
Why?
| | Eye Enucleation | 1 | 1993 | 11 | 0.010 |
Why?
| | Didanosine | 1 | 1993 | 13 | 0.010 |
Why?
| | Viral Proteins | 2 | 1985 | 321 | 0.010 |
Why?
| | Zidovudine | 1 | 1993 | 77 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1993 | 82 | 0.010 |
Why?
| | Mice | 2 | 1986 | 16579 | 0.010 |
Why?
| | Neutrophils | 2 | 1987 | 1188 | 0.010 |
Why?
| | Cell Cycle | 1 | 1994 | 581 | 0.010 |
Why?
| | HLA-DP Antigens | 1 | 1991 | 32 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 1991 | 231 | 0.010 |
Why?
| | Thromboxane A2 | 1 | 1990 | 11 | 0.010 |
Why?
| | Histocompatibility Testing | 1 | 1990 | 120 | 0.010 |
Why?
| | Leukotriene B4 | 1 | 1990 | 40 | 0.010 |
Why?
| | Antigen-Presenting Cells | 1 | 1990 | 150 | 0.010 |
Why?
| | Biological Assay | 1 | 1991 | 118 | 0.010 |
Why?
| | Radioimmunoassay | 1 | 1990 | 169 | 0.010 |
Why?
| | Aspartate Aminotransferases | 1 | 1990 | 85 | 0.010 |
Why?
| | Immunophenotyping | 1 | 1991 | 312 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 1990 | 142 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 1990 | 150 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 1992 | 410 | 0.010 |
Why?
| | Epoprostenol | 1 | 1990 | 134 | 0.010 |
Why?
| | Immunoglobulins | 1 | 1990 | 157 | 0.000 |
Why?
| | Coroners and Medical Examiners | 1 | 1989 | 7 | 0.000 |
Why?
| | Virus Cultivation | 1 | 1989 | 28 | 0.000 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 1992 | 249 | 0.000 |
Why?
| | Adrenal Cortex | 1 | 1988 | 27 | 0.000 |
Why?
| | Methods | 1 | 1988 | 65 | 0.000 |
Why?
| | Arterioles | 1 | 1988 | 40 | 0.000 |
Why?
| | Chemical Fractionation | 1 | 1988 | 29 | 0.000 |
Why?
| | Survival Rate | 1 | 1993 | 1872 | 0.000 |
Why?
| | Metaraminol | 1 | 1987 | 1 | 0.000 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 1988 | 93 | 0.000 |
Why?
| | Rats, Inbred WKY | 1 | 1987 | 33 | 0.000 |
Why?
| | Rats, Inbred SHR | 1 | 1987 | 43 | 0.000 |
Why?
| | Peroxidases | 1 | 1987 | 30 | 0.000 |
Why?
| | Mannitol | 1 | 1987 | 35 | 0.000 |
Why?
| | Adrenal Gland Neoplasms | 1 | 1988 | 83 | 0.000 |
Why?
| | Cell Membrane Permeability | 1 | 1987 | 80 | 0.000 |
Why?
| | Edetic Acid | 1 | 1987 | 46 | 0.000 |
Why?
| | Propionibacterium | 1 | 1986 | 2 | 0.000 |
Why?
| | AIDS-Related Complex | 1 | 1986 | 3 | 0.000 |
Why?
| | HIV Antigens | 1 | 1987 | 17 | 0.000 |
Why?
| | Serum Albumin, Bovine | 1 | 1987 | 61 | 0.000 |
Why?
| | Leukocyte Count | 1 | 1988 | 327 | 0.000 |
Why?
| | Mitosis | 1 | 1988 | 178 | 0.000 |
Why?
| | Carcinoma | 1 | 1988 | 214 | 0.000 |
Why?
| | Blood-Brain Barrier | 1 | 1987 | 129 | 0.000 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1986 | 42 | 0.000 |
Why?
| | Argon | 1 | 1986 | 21 | 0.000 |
Why?
| | Cell Division | 1 | 1988 | 779 | 0.000 |
Why?
| | Antigens, Viral | 1 | 1987 | 174 | 0.000 |
Why?
| | Homosexuality | 1 | 1986 | 14 | 0.000 |
Why?
| | Agranulocytosis | 1 | 1986 | 32 | 0.000 |
Why?
| | Interleukin-1 | 1 | 1990 | 961 | 0.000 |
Why?
| | Hydrogen Peroxide | 1 | 1987 | 308 | 0.000 |
Why?
| | Amino Acid Sequence | 1 | 1990 | 2041 | 0.000 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1985 | 34 | 0.000 |
Why?
| | Light | 1 | 1988 | 355 | 0.000 |
Why?
| | Regional Blood Flow | 1 | 1987 | 462 | 0.000 |
Why?
| | Drug Synergism | 1 | 1986 | 358 | 0.000 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1986 | 168 | 0.000 |
Why?
| | Biomarkers, Tumor | 1 | 1992 | 1182 | 0.000 |
Why?
| | Autoantigens | 1 | 1988 | 416 | 0.000 |
Why?
| | Molecular Sequence Data | 1 | 1990 | 2818 | 0.000 |
Why?
| | Tissue and Organ Procurement | 1 | 1989 | 288 | 0.000 |
Why?
| | Pilot Projects | 1 | 1990 | 1558 | 0.000 |
Why?
| | Anterior Eye Segment | 1 | 1985 | 9 | 0.000 |
Why?
| | HLA-B27 Antigen | 1 | 1985 | 15 | 0.000 |
Why?
| | DNA | 1 | 1992 | 1392 | 0.000 |
Why?
| | Hyperemia | 1 | 1985 | 48 | 0.000 |
Why?
| | Lymphokines | 1 | 1984 | 115 | 0.000 |
Why?
| | Structure-Activity Relationship | 1 | 1986 | 530 | 0.000 |
Why?
| | Gram-Negative Bacteria | 1 | 1985 | 69 | 0.000 |
Why?
| | Brain Neoplasms | 1 | 1993 | 1149 | 0.000 |
Why?
| | Indians, North American | 1 | 1990 | 600 | 0.000 |
Why?
| | Epithelial Cells | 1 | 1991 | 1036 | 0.000 |
Why?
| | Ischemia | 1 | 1987 | 395 | 0.000 |
Why?
| | Monocytes | 1 | 1987 | 541 | 0.000 |
Why?
| | Hodgkin Disease | 1 | 1986 | 134 | 0.000 |
Why?
| | Cryptococcosis | 1 | 1984 | 25 | 0.000 |
Why?
| | Prevalence | 1 | 1990 | 2549 | 0.000 |
Why?
| | Lymphatic Diseases | 1 | 1983 | 21 | 0.000 |
Why?
| | alpha 1-Antitrypsin | 1 | 1985 | 103 | 0.000 |
Why?
| | Clone Cells | 1 | 1984 | 254 | 0.000 |
Why?
| | Colitis | 1 | 1986 | 240 | 0.000 |
Why?
| | Antibodies, Viral | 1 | 1986 | 593 | 0.000 |
Why?
| | Pain | 1 | 1988 | 756 | 0.000 |
Why?
| | Meningitis | 1 | 1984 | 80 | 0.000 |
Why?
| | Microscopy, Fluorescence | 1 | 1984 | 402 | 0.000 |
Why?
| | Kidney Transplantation | 1 | 1988 | 604 | 0.000 |
Why?
| | Endothelium, Vascular | 1 | 1988 | 871 | 0.000 |
Why?
| | Biomechanical Phenomena | 1 | 1985 | 778 | 0.000 |
Why?
| | Mice, Inbred BALB C | 1 | 1984 | 1229 | 0.000 |
Why?
| | Vasodilation | 1 | 1985 | 478 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1986 | 998 | 0.000 |
Why?
| | Pneumonia, Viral | 1 | 1986 | 339 | 0.000 |
Why?
| | Blood Pressure | 1 | 1987 | 1733 | 0.000 |
Why?
| | Killer Cells, Natural | 1 | 1983 | 425 | 0.000 |
Why?
| | Sexual Behavior | 1 | 1984 | 477 | 0.000 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 1984 | 377 | 0.000 |
Why?
| | Lung | 1 | 1985 | 3741 | 0.000 |
Why?
|
|
Palestine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|